Hakan Edstrom, MannKind Corp.’s CEO, is a patient man. His biopharmaceutical company has the technology to turn it into a $2 billion business. However, acceptance of their patented product to deliver drugs in inhalable form has been slow. The company’s flagship product is Afrezza, a rapid-acting insulin inhalant. “When you start something which is a…
This content is for Westfair Online members only. Please Sign in / Join to view this content. Become a member by Registering Here.
